MAM
ADOHM comes on board as sponsors for Bloomberg|Quint’s web -series ‘Brandsmiths’
MUMBAI: ADOHM, a new age marketing platform powered by artificial intelligence, has come on board as the sponsor for Bloomberg|Quint’s web -series Brandsmiths. The series is an effort to showcase excellence of teams that are custodians of the brand and have created path breaking marketing campaigns to catapult the brand to success.
Speaking on the same, ADOHM co-founder Kuldeep Chaudhury said, “We are glad to partner with Bloomberg|Quint for their web-series Brandsmiths. This platform has a unique reach and we are sure we will be able to reach out to maximum audience with this association.”
Commenting on the association, BloombergQuint CEO Anil Uniyal said, “In this season of Brandsmiths, we speak with some of the best marketing practitioners in the country & try to understand their perspective on building brand salience in this era of technology dominated by Artificial Intelligence. We could not find a better partner but ADOHM for the same.”
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
